Cambridge Healthtech Institute’s 4th Annual
RNA Development, CMC, and Manufacturing
August 18-19, 2025
RNA technology has undergone transformative evolution in recent years with major advancements in mRNA- and RNA-based vaccines, and therapies such as circular RNA, RNAi, saRNA, and antisense oligonucleotide (ASOs). CHI’s 4th Annual RNA Development, CMC, and Manufacturing conference delves into the technical challenges associated with bringing these therapies from early-stage development to commercial success, from CMC best practice to intricate analytics and characterization methodologies. Featuring ongoing advancements in scalable and cost-effective manufacturing, we aim to explore the latest breakthroughs, address challenges, and pave the way for the continued success of RNA- and mRNA-based therapeutics and vaccines for personalized and large indications.
Coverage will include, but is not limited to:
- CMC, Harmonization, and Regulatory Standards
- Raw Materials and Supply Chain
- Analytics: Product and Process Characterization to Improve Quality
- Process Development: Scaling and Purification
- Lipid Nanoparticle (LNP) Analytics and Manufacturing
- Tech Transfer and Outsourcing
The deadline for priority consideration is January 27, 2025.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: